


Appendix

Table 1: Comparison of the dry-eye-related ocular surface manifestation between post-COVID patients and healthy individuals:

	Post-COVID patients	Healthy individuals
Meibomian gland dysfunction staging#	1.14±0.67**	0.92±0.68
Proportion of eyes with any positive corneal fluorescein staining	48.9%*	38.6%
Corneal fluorescein staining score#	0.60±0.69*	0.49±0.68


Remarks: Statistical significance *p<0.05, **p<0.005
Graded on a 4-point scale (0=absent, 1=mild, 2=moderate, 3=severe)

Corneal fluorescein staining



Graded on a 4-point scale (0=absent, 1=mild, 2=moderate, 3=severe)

Meibomian gland dysfunction staging



Graded on a 4-point scale (0=absent, 1=mild, 2=moderate, 3=severe)

Table 2: Summary of the prevalence of recent-onset dry eye symptoms among post-COVID patients:

Dry eye symptoms	Percentages of post-COVID patients presenting related symptoms
Blurring	9.2%
Itch	6.1%
Pain or burning sensation	4.8%
Tearing or discharge	3.9%
Redness	3.1%
Grittiness	2.2%
Light-sensitivity	1.8%
Lid swelling	1.3%
One or more than one related symptoms	21.5%